1 / 13

Myths and Facts Quiz

Myths and Facts Quiz. Depletion and repletion dynamics of B cells: The impact on the practical use of selective B cell therapy in RA. Findings from Workshop 2 Professor Paul-Peter Tak Academic Medical Center (AMC)/University of Amsterdam, Amsterdam, the Netherlands.

libra
Download Presentation

Myths and Facts Quiz

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Myths and Facts Quiz

  2. Depletion and repletion dynamics of B cells: The impact on the practical use of selective B cell therapy in RA Findings from Workshop 2 Professor Paul-Peter Tak Academic Medical Center (AMC)/University ofAmsterdam, Amsterdam, the Netherlands

  3. Depletion and repletion dynamics of B cells: The impact on the practical use of selective B cell therapy in RA

  4. Workshop 2: Key findings (1) • B cells appear to orchestrate local cellular infiltration • Kinetics of the tissue response suggest that rituximab exerts its effects, in part, by an indirect effect on B cell-derived plasma cells associated with autoantibody production • Highly sensitive flow cytometry reveals variable peripheral blood B cell depletion • Failure to respond to rituximab is explained by failure to deplete B lineage cells in blood and synovium

  5. Workshop 2: Key findings (2) • Rituximab is well tolerated over multiple courses — AEs, SAEs and infections remain stable over time with no occurrence of tuberculosis • Rate and nature of SIEs following other biologics remain consistent with those observed during rituximab treatment • Ability to mount protective responses following active tetanus toxoid immunisation and DTH skin test remains intact with rituximab

More Related